Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
TLSA share price must reach $1 by end of play Tuesday 16th January, or we are booted off NASDAQ. Very good news today, so what else a GC got up his sleeve to boost the share price?
We believe the risk reduction could be substantial with combination therapy.”
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced filing of a new patent application relating to composition and methods for combining GLP-1ra and foralumab, a fully human anti-CD3 antibody, to achieve further reductions in systemic and vascular inflammation associated with Type 2 Diabetes (T2D) and also in a separate population of patients with non T2D obesity.
Effectiveness of GLP-1ra non T2D obesity was recently shown in the >17,600 patient SELECT trial by Novo Nordisk (N Engl J Med 2023; 389:2221-2232(NCT03574597). SELECT showed a 20% reduction of major adverse cardiovascular events (MACE) such as heart attack, stroke, and peripheral vascular disease, with semaglutide. The risk of adverse cardiovascular events could be reduced further by the combination of intranasal foralumab and a GLP-1ra. The patent application describes the potential for foralumab to provide additional risk reduction for heart attack, stroke, and peripheral vascular disease. Foralumab given with GLP-1ra may contribute importantly to further risk reduction in this at-risk patient population.
“The GLP-1ra’s have revolutionized the treatment of obesity and type 2 diabetes. Obesity and type 2 diabetes are associated with inflammation in the liver, adipose and vascular tissue. This inflammation contributes to the pathogenesis of stroke,” commented Howard L. Weiner M.D. from Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System and Professor of Neurology. “Although effective, GLP-1ra’s do not completely mitigate the disease process and are associated with various side effects. Intranasal foralumab, a fully human anti-CD3, has shown efficacy in attenuating inflammation in humans with multiple sclerosis and COVID. Because intranasal foralumab induces regulatory T cells in a physiologic fashion, foralumab has novel anti-inflammatory properties that make it applicable to multiple disease conditions. Furthermore, it has had minimal side effects in both human and animal studies. We have now discovered intranasal anti-CD3’s positive effect in models of diet-induced obesity related to mitigating its complications. Intranasal anti-CD3 therapy also dramatically decreases inflammation and metabolic changes. Thus, we believe it has the potential to be an ideal therapy to be given in combination with the class of GLP-1ra approved drugs.”
Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences said, “I believe that our commitment to improving patient outcomes by using anti-CD3, or foralumab, in risk mitigation for MACE could be another exciting indication for foralumab. We hope our efforts will give a new therapeutic option to patients afflicted with Type 2 Diabetes and non T2D obesity that are receiving GLP-1 receptor antagonists. We believe the risk reduction could be substantial with com
No updates for 5 or 6 months. Obviously no cash left, no results, no SPO, no anything?…
Is going pop or is there funding? What’s the plan? BOD do you fancy updating shareholders? I know it’s only been 3 years so far but would a 5 min interview hurt?…
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced “first patient dosed” in its Phase 2a study comparing two doses of intranasal foralumab and placebo in patients with non-active secondary-progressive multiple sclerosis (na-SPMS). Six investigational centers have been recruited for this double-blind, placebo-controlled trial, with up to 18 patients per treatment arm. The primary endpoint of the trial will be the change in microglial activation based on PET scans. Clinical evaluations include the Expanded Disability Status Scale (EDSS), QoL assessments, and the Modified Fatigue Impact Scale (MFIS), which assess parameters that are essential to a patient’s everyday life. Novel immuno-biomarkers will be measured also and assessed for predictive relevance. Central review of PET scans and images is an integral component of this study.
"The successful consenting, screening, completion of the baseline PET scan, and dosing of our first patient in the intranasal foralumab Phase 2a trial has occurred seamlessly,” said Tanuja Chitnis, M.D., the Principal Investigator at Brigham and Women’s Hospital, a founding member-hospital of Mass General Brigham Healthcare System, and Professor of Neurology at Harvard Medical School. “My anticipation is this randomized placebo-controlled trial is the first step in bringing this potential treatment to patients that have na-SPMS, a disease with no approved therapy. Our experience in the Expanded Access Program provides sustainable hope for relief of symptoms in these patients with an unmet medical need.”
Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences said, “I believe that our dosing of the first patient confirms Tiziana’s ability to execute on its commitments and potential to advance our fully human intranasal anti-CD3 mAb, foralumab, using novel imaging methods and clinically relevant endpoints. We hope our efforts will give a new therapeutic option to patients afflicted with this devastating disease. Currently, there are no FDA approved treatments for na-SPMS.”
Matthew W. Davis, MD, RPh, Chief Operating Officer and Chief Medical Officer of Tiziana, added, “I am very pleased the first patient has been dosed and our team is committed to remaining on track with our milestones. We are poised to accelerate enrollment and anticipate data readout in Q4 2024. I believe the study results will reveal important aspects for optimizing clinical management of na-SPMS - particularly the potential for a reduction in MFIS scores.”
https://www.tizianalifesciences.com/news-item?s=2023-12-19-tiziana-life-sciences-doses-first-patient-in-phase-2a-trial-of-intranasal-foralumab-in-multiple-sclerosis
I wonder if we will get an update on accustem any time soon. It’s what, 5 months? Since the last accustem update
Tiziana Life Sciences Ltd
TLSA Bid Price NCM 7/19/2023
So I guess there'll be some serious ramping soon.
Beening selfish here but hope it's January. Late January thank again rockz
Hi Jimmy. We are looking at December/January for an update. Accustem have had access to historical breast cancer samples which have been stored at University Hospitals for over a decade. Accustem have been able to use this information to further validate the original StemprintER results.
Hello rockz what sort of time period do you call shortly.
Was hoping nothing would happen for a while waiting for some money to get freed up so I can top up with some accustem thanks for the information in advance
An update is due shortly from the Accustem collaboration with University Hospital, Cleveland.
What’s happening with accustem?
What’s happening with accustem?
What’s happening wit…..
The company has successfully enrolled and dosed four new patients with non-active secondary progressive multiple sclerosis (na-SPMS) in the Brigham and Women’s Hospital
https://ir.tizianalifesciences.com/news-releases/news-release-details/tiziana-life-sciences-announces-foralumab-dosing-four-new
Any clues as to how they are still a going concern given that the wage bill would seem to exceed the cash on hand?
Won’t be making any more excuses for GC but the outlook has been pretty darn poor. Will they ever uplist to the Nasdaq? What is the best way forward to get funding and deliver some kind of shareholder value?
Watch accustem interview with proactive
Anything happening with this bum stock now?
Have the BOD fleeced and drained Tiziana sufficiently yet as well?
$57m dollar raise.
What did that achieve?
Aside from lending money to keep other bum companies afloat
Apparently it broke $1.30 in April. I don't think recent falls can be blamed on my very minor slicing. Still, @ $0.56, glad I did.
This share ever go up ? Or progress any soon ?
So, accustem had around $71k dollars at the end of September- not a lot of runway.
Are we about to receive another update? Is there funding?..
I see. Yes there seem to be piles of competitors to this I wonder if it’s not that special after all. As usual no update, not even a comment from the plumber. Must be going really well or even more poor that we’ve become accustomed to
Latest share price ACUT is $0.75. So not too bad.
Saw a news item yesterday (can`t remember what) which made me think if it were a success it would render stemprinter redundant. Market catch up today?
At the ex date I believe it was around £1.80 a share for Tiziana shared and there has been a 20/1 consolidation since then.
To have 1 accustem share now you would have needed 20 Tiziana Uk shares at a cost of approx £36 at ex date .
That makes the cost of 1 share approx 1.8% of what it was in October 2020.
Still, expensive if it goes pop…
Or a large upside if we haven’t been sold a pup… an update would sure be nice
Down 53% wtf
Either that or they’re out of cash.
Wasn’t their burn rate around $100k a month and they had $100k left a few months ago ?
3 years since ex date. Shareholders not kept in the loop in my opinion. One interview from Wendy Blosser (Who incidentally I think is a strong executive), but no update on the ipo/spo really and nothing particularly exciting.